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ABSTRACT 
The PER3 gene is a member of a conserved family of genes linked to control of the circadian cycle in 
flies, mice and humans. We show that deletion of the PER3 gene located on human chromosome 1p36 is 
directly related to tumor recurrence in patients with estrogen receptor (ER) positive breast cancers treated 
with Tamoxifen. Low expression of PER3 mRNA is associated with poor prognosis, particularly in a 
subset of tumors that are ER-positive, and either luminal-A type or ERBB2-positive tumors. Mice 
deficient in Per3 showed increased susceptibility to breast cancer induced by carcinogen treatment or by 
over-expression of Erbb2. Epidemiological evidence suggests that disruption of sleep patterns plays a 
significant role in susceptibility to breast cancer, and inherited genetic variants in PER3 have previously 
been associated with both phenotypes. Disruption of PER3 function could provide a link between 
deregulation of sleep homeostasis and breast tumorigenesis, and may serve as an indicator of probability 
of tumor recurrence in patients with ER-positive tumors.  
 INTRODUCTION 
Chromosomal region 1p36 is among the most commonly deleted regions in human cancers. 
Deletion of 1p36 is especially frequent in breast tumors and is associated with progression and lymph 
node metastasis1, poor prognosis2 higher rate of recurrence3, larger tumor size and DNA aneuploidy4. 
However, no direct relationship between breast carcinogenesis or prognosis and any specific tumor 
suppressor gene on 1p36 has been established. Recent elegant studies have identified CHD55 and more 
recently KIF1B6 as candidate tumor suppressor genes in this region, but no specific roles for these genes 
in breast cancer development have been demonstrated.  
The human PER3 gene is located within 1.5Mb of CHD5, and the mouse homologue is a member 
of the Period gene family that controls circadian rhythms7,8. Members of the Period family of circadian 
rhythm genes (Per1 and Per2) have been implicated in cell cycle control, DNA damage responses and 
tumor progression9-13. Although inactivation of mPer3 in the mouse germline has only  subtle effects on 
circadian clock function14, it has been shown that mPer3 transcripts exhibit a clear circadian rhythm both 
in the suprachiasmatic nucleus (SCN)7 and in mouse peripheral tissues15. Similar data have been shown in 
human peripheral blood cells, where circadian oscillations were more robust for PER3 expression than for 
other clock genes including PER1 and PER216,17. The possible functions of PER3 in tumor development 
have not been explored, but links to breast cancer are supported by biochemical studies demonstrating the 
existence of complexes including proteins of the PER family together with the estrogen receptor18,19, and 
by reports of association between a polymorphism in the human PER3 gene and breast cancer 
susceptibility20.  
  The location of the PER3 gene within a region that is commonly deleted in breast cancers 
suggested a possible link to epidemiological studies showing an association between disrupted sleep 
cycles and higher risk higher risk of developing breast cancer21,22. We used a combination of human 
breast tumor analysis and mouse models to show that disruption of PER3 may serve as a prognostic 
biomarker of tumor recurrence in patients with ER+, Luminal A and/or ERBB2+ tumors. 
 RESULTS 
Deletion of 1p36 and loss of PER3 genetic variants in breast cancers. 
We previously reported genome-wide array CGH profiles of 185 lymph node negative breast 
cancers from a Spanish cohort23, of whom 85 received anthracycline chemotherapy (Chemo group), and 
95 received no chemotherapy (non-Chemo group). To search for genetic events related to resistance to 
hormonal (Tamoxifen) therapy, we divided the non-Chemo group into two subgroups based on whether 
they had received hormonal treatment. Of the 95 patients in the non-Chemo group, 59 patients with ER 
and/or PgR positive tumors received Tamoxifen, whereas 36 did not receive any treatment. Analysis of 
CGH profiles for these patients revealed that deletion of chromosome 1p was associated with recurrence 
in this subgroup of ER+ Tamoxifen treated patients (p < 0.05 after multiple testing correction using 
method of Benjamini & Hoffberg) (Supplementary Fig. 1).  
 The chromosome 1p36 locus is frequently deleted in many human tumors, but the region of 
deletion is large, and separate, non-overlapping chromosome fragments have been implicated24-26. This 
suggests that multiple tumor suppressor genes are involved. We considered PER3 to be a good candidate 
for involvement in breast cancer because of its location within one of the minimal deletion regions on 
1p36.2 (Refs. 5,6), as well as the epidemiological20 and mechanistic18 data linking circadian rhythm genes 
to hormone status and breast cancer. We therefore examined the copy number status of PER3 by 
quantitative TaqMan analysis in DNA samples from 180 breast cancer patients. The relationship between 
the frequency of deletion or copy number gain and clinico-pathological characteristics of the patients is 
shown in Supplementary Table 1.  The number of copies of PER3 showed a significant gene dosage 
association with recurrence-free survival at 10 years (Fig. 1a, p= 0.01).  The proportion of disease free 
surviving patients after 10 years was lowest in patients with single copy PER3 deletion (56% ± 8.6; red 
line) , compared to those with two (75% ± 4.0; blue line) or more (89% ± 5.6; green line) copies of the 
PER3 gene (Fig. 1a).  Further analysis showed that the effect of PER3 deletion was most pronounced in 
the Tamoxifen treated group, with no significant association in the non-treated or chemotherapy-treated 
groups (Figs.1b-d). Among the 59 patients who only received Tamoxifen treatment (Fig. 1d), patients 
with single copy PER3 deletions had a significantly lower disease-free survival rate at 10 years (47% 
±12) than those with normal PER3 (84%±6) or copy number gains (100% survival) (p=0.007).  To look 
for potential inactivating mutations in PER3 in breast cancers, we initially sequenced the complete coding 
region of PER3 in a panel of 35 breast cancer cell lines. No clear pathogenic (nonsense or missense) 
mutation was identified. However many known27 and some other unknown polymorphisms and 
alternative splicing isoforms were found (see online supplementary data for full detailed description). One 
of the polymorphic variants identified by sequencing had been associated in other studies with breast 
cancer susceptibility20 and also with disruption of sleep homeostasis28-30 
 
Low expression of PER3 is associated with reduced survival 
We next examined PER3 gene expression in 413 breast tumor expression arrays taken from two 
publicly available data sets (Van de Vijver31 2002, n=295 and Chin32 2007, n=118).  A full description of 
the stratification of the patients into different subgroups according to PER3 expression together with 
disease-free survival curves for all patients in each sub-group is shown in Figures 2 and 3. Patients with 
lower PER3 expression (“PER3 low”, n=122) were significantly more likely to recur than those with 
normal or higher expression (“PER3 normal/high”, n=291) (Fig. 2a; p=0.013).  Disease-free survival 
analysis showed that PER3 low patients had significantly worse survival rates than PER3 normal/high 
patients (p<0.001). ER status is an important predictor of recurrence and greatly influences treatment 
regimes33,34.  If low expression of PER3 segregates with ER status, any effect of low PER3 expression 
could be confounded with the effect of ER status.  We therefore performed a subset analysis of PER3 in 
ER+ and ER- tumors.  Low PER3 levels were significantly associated with recurrence (p= 0.01) and 
shorter disease-free survival times (p<0.001) in patients with ER+, but not ER- tumors (Fig. 2b).  We 
conclude that the association between low PER3 expression and recurrence in the complete patient 
sample set was driven by the ER+ tumors, with no effect being detected in the ER- tumors. These data are 
in agreement with the independent association between deletion of PER3 and recurrence specifically in 
the Tamoxifen-treated (ER positive) patients in Figure 1d.  
We next asked whether stratifying tumors according to their molecular subtype35,36 could reveal 
additional information.  The tumors were labeled using a nearest centroid classifier and a label was only 
assigned if correlation with a target class was above 0.1 (Refs. 31,32).  This resulted in samples labeled 
Luminal A (n=90), Luminal B (n=68), ERBB2 (n=56), Normal-like (n=17), Basal (n=73), or Unclassified 
(n=109) (Fig. 3 and supplementary Fig 4).  Of these groups, low PER3 expression had significant 
association with recurrence only in Luminal A-type (p=0.007) or ERBB2-type tumors (p=0.03) (Fig. 3b). 
Disease-free survival analysis for Luminal A and ERBB2-type tumors indicated that PER3 low patients 
had lower disease free survival rates at 10 years than those patients with PER3 normal/high (28%± 10 vs 
84%±4) for Luminal A (p<0.001) and (30%± 8 vs 68%±8) for ERBB2-type (p= 0.004). There was also a 
striking effect on overall survival rate at 10 years in all the patients and in the subgroups of ER positive, 
Luminal A and ERBB2 patients (Fig. 4):  The ten year overall survival rate for ER+ patients with low 
PER3 was 55% ± 6 vs. 79% ± 3 for normal/high patients (p < 0.001) (Fig. 4b). The overall survival rate 
was 25% ± 8 for ERBB2 patients with low PER3, vs. 70% ± 7 for ERBB2 patients with normal/high 
PER3 (p<0.001) (Fig. 4f).  The overall Survival rate at 10 years in Luminal-A patients with low PER3 
was 34% ± 11 vs. 83% ± 3 for patients with normal/high PER3 (p<0.001) (Fig. 4g). Importantly, 
multivariate analysis showed that PER3 expression is significant independently from all the prognostic 
factors tested both for Disease Free Survival (p<0.001) and Overall survival (p=0.001) (Table 1).   
We next evaluated possible links between expression levels and probability of tumor recurrence 
for all 54 annotated genes in the 1p36.31-1p36.22 (chr1:6,084,440-9,512,808 (3.5 Mb in size)) region. 
Gene expression was discretized as described for PER3 and log rank p values were calculated using the 
survival library for R. This analysis showed that PER3 was the only gene with an uncorrected p < 0.05 in 
all data sets analyzed. Although chromosome engineering studies have previously identified CHD5 as a 
candidate tumor suppressor gene within the minimal deletion region on 1p36.2 (Ref. 5), no association of 
CHD5 expression levels with recurrence or survival was found in any of the subgroups of breast cancer 
patients analyzed (Supplementary Figs. 5 and 6). These data do not exclude the possibility that CHD5 
plays an important role as a tumor suppressor in other tumor types.  
 
Inactivation of Per3 increases breast tumor susceptibility in mouse models.  
In order to investigate a possible causal association between loss of Per3 function and breast 
tumor development, we performed two studies involving mouse models of breast cancer. A total of 86 
mice carrying normal or inactivated alleles of the Per3 gene (17 wild-type Per3+/+, 35 heterozygous 
Per3+/- and 34 null Per3-/-) were treated by oral gavage with 7, 12-dimethylbenz[a]anthracene (DMBA), a 
protocol known to induce breast cancer in sensitive strains of mice37.  Eight mice (two heterozygous and 
six null) were found dead before the end point and no tissues were collected from them. The median 
follow-up of the remaining 78 mice included in the study was 8.3 months (range 3.8 – 15.0).  All of the 
mice treated with DMBA developed tumors of various kinds including lymphoma and solid tumors of the 
lung, ovary, and skin (Supplementary table 5).  However, development of breast tumors was specifically 
associated with Per3 deficiency. Thirty-six percent of Per3-/- mice treated with DMBA developed breast 
tumors, while 12% of the Per3+/- mice developed breast tumors.  In striking contrast, none of the control 
Per3+/+ mice developed a breast tumor (p= 0.005) (Fig. 3a).  A group of 65 mice (19 wild-type, 25 
heterozygous, and 21 null) were used as controls with no DMBA gavage treatment.  Two of the Per3-/- 
control mice developed sporadic breast tumors, but none of the remaining mice were found sick or 
developed any other class of tumor during the time course of this experiment (24 months).  
The second mouse model was based on the observation that low levels of Per3 expression were 
strongly associated with recurrence in ERBB2-type human breast cancers.  MMTV-Neu mice overexpress 
ErbB2 in the mammary gland, and spontaneously develop breast tumors38. We generated a total of 79 
MMTV-Neu positive mice of which 30 (38%) were Per3+/+, 35 (44%) were Per3+/-, and 14 (18%) were 
Per3-/-. The median follow-up of all mice was 14.9 months (range 6.3 – 25.8). All Per3-/- mice developed 
breast tumors, whereas 25 (71%) of the Per3+/-and 14 (47%) of the Per3+/+ mice developed breast tumors. 
The proportion of Per3-/-null mice free of tumors at 15 months (21% ± 8) was significantly lower than the 
proportion in the heterozygous and the wild-type mice (63% ±6 in both Per3+/- and Per3+/+, p = 0.003). 
Histological analysis of tumors from both models of breast cancer showed that loss of Per3 did not affect 
the tumor class or morphology, since both DMBA-induced and MMTV-Neu-induced tumors in Per3-/- 
mice resembled equivalent tumors from Per3 wild type animals (data not shown). We also evaluated the 
possible loss of the wild type Per3 allele in tumors from the Per3 heterozygous mice. No loss was 
observed suggesting that homozygous loss is not essential in this mouse model. 
 
DISCUSSION 
Our data indicate that deletion and/or reduced expression of the PER3 gene on human 
chromosome 1p36 is associated with breast cancer recurrence, particularly in ER+ patients treated with 
Tamoxifen who did not receive chemotherapy. No effect of deletion was seen in patients with basal type 
ER- breast tumors. Within the ER+ category, the effect was primarily in tumors classified as Luminal A 
or ERBB2, but not in the Luminal B type which share some expression features with basal tumors35,36. 
Direct evidence for a causal role for loss of PER3, rather than an alternative gene in this commonly 
deleted region of the genome5,6, comes from analysis of two different mouse models of breast cancer.  
Both chemically-induced and Neu(ErbB2)-induced breast cancers are increased in frequency and/or 
reduced in latency in mice carrying inactivated Per3 alleles. Although these data do not prove that Per3 is 
the only functional tumor suppressor gene in this chromosome interval, they indicate that Per3 is a bona 
fide tumor suppressor in these mouse models, with a key role in breast tissue.  
While disruption of the mouse Period gene family members Per1 and Per2 by gene targeting 
induces biological clock phenotypes39, loss of Per3 function induces only subtle effects on circadian 
rhythm14,40 . Nevertheless, evidence in favor of PER3 involvement both in sleep disruption and in breast 
cancer comes from studies of a human structural polymorphism in the PER3 coding sequence that has 
been associated with delayed sleep phase syndrome, diurnal preference and waking performance28,41,42, 
but also with increased breast cancer risk20, particularly in premenopausal women.  
Although the specific molecular mechanisms remain to be elucidated, increasing evidence points 
to a role for circadian rhythm genes in cell cycle control and DNA damage responses11,43 as well as in 
hormonal control of gene expression18,19.  PER2 has been identified as an estrogen-inducible ER co-
repressor that forms heterodimers with PER3 to enter the nucleus. Deletion of PER3 prevents nuclear 
import, and instead promotes accumulation of PER2 in the cytoplasm44. Whether coordinated functional 
deregulation of all PERIOD family genes occurs in breast cancers remains to be determined. Elucidation 
of the relationship between control of sleep homeostasis and circadian rhythms, PER gene expression and 
DNA damage responses may help in understanding the epidemiological data linking sleep disruption to 
breast cancer susceptibility18,21,22, but further detailed studies will be required to elucidate the exact 
mechanisms involved.   
 METHODS 
 
SAMPLE SELECTION 
We used three previously published breast cancer data sets that included clinical, gene expression 
and/or array Comparative Genomic Hybridization (CGH) data31,32. Data on disease-free survival (defined 
as the time to a first event) and overall survival were available for all the patients in the three data sets 
except one patient in the Chin et al.32 samples.   
 
COPY NUMBER ANALYSIS OF PER3 
All tumor DNA samples were obtained from frozen breast tumors with >50% tumor cells23. The 
genomic sequence of PER3 (GenBank accession NM_016831.1) was used to design a set of primers and 
probe specific to the PER3 gene (Primer Express software version 1.0 (Applied Biosystems)). The 
primers for PER3 were 5’- GGAGTGAGAAACCGGTGTCTGT-3’ (forward) and 5’- 
GCCCGCAGCCTGCTT -3’ (reverse). The probe for PER3 was 5’-(6-FAM) - 
CTGACTGCAAAGTGAG-(TAMRA)-3’, where FAM is 6-carboxyfluorescein and TAMRA is 6-
carboxytetramethylrhodamine. The primers and probe for RNase P used as an endogenous control gene 
were obtained from Applied Biosystems. The RNase P probe was labeled at 5’ end with VIC (Applied 
Biosystems) instead of FAM. PER3 copy number was determined by relative quantification using the 
ΔΔCt method normalized to the RNase P copy number of two45. To analyze the results from the copy 
number experiment we used the TaqMan® Gene Copy Number Assays Macro File (Applied Biosystems). 
 
ISOLATION and SEQUENCING OF PER3 cDNA. 
We analyzed the sequence of PER3 cDNA in 35 breast cancer cell lines (see supplementary 
Tables 2 and 3, and Supplementary Fig. 2). No evidence for the presence of any non-conservative tumor-
specific structural changes was detected, although several known polymorphisms were found in this 
analysis.   
 
PER3 GENE EXPRESSION ANALYSIS 
We examined PER3 expression in 413 breast tumor expression arrays taken from Van de Vijver31 
2002 (n=295) and Chin32 2007 (n=118).  In each dataset a sample si in the set S was labeled as “PER3 
Low”, “PER3 normal”, or “PER3 high” using the rule:  
 If  si ≤ ( mean[S] - ½ *standard deviation[S] ), assign LOW 
 If  si ≥ (mean[S] + ½ *standard deviation[S]), assign HIGH 
  Otherwise, assign NORMAL.   
This method allowed us to compare relative PER3 expression levels across both data sets fused as a single 
group of patients. 
 
STATISTICAL ANALYSIS 
The association between PER3 deletion or PER3 expression and clinical-pathological parameters was 
analyzed using Fisher’s Exact test. All reported P values were two tailed. Significant differences in 
disease-free and overall survival time were calculated using the Cox proportional hazard (log-rank) test. 
Multivariate Cox Regression Analysis was used to prove statistical independence of PER3 from other 
known prognostic factors. Statistical analysis was performed using SPSS version 12.0. 
 
MICE AND TUMOR INDUCTION 
Wild-type (Per3+/+) and Per3 knockout (Per3-/-) 129/sv mice (provided by Drs. YH Fu and LJ 
Ptáček, UCSF) were bred and treated according to Laboratory Animal Resource Center (LARC) 
regulations.  7-week-old female mice from the F2 intercross population (Per3+/+, Per3+/- and Per3-/-  )  were 
treated with 6 doses of 1 mg of 7, 12-dimethylbenz[a]anthracene (DMBA) diluted in corn oil by weekly 
oral gavage. A second group of mice was treated only with corn oil as a group control. In a second 
experiment, male Per3-/- mice were crossed with female FVB mice expressing the Neu (ErbB2) 
protooncogene under control of the MMTV 3’-LTR promoter38 (provided by Dr. Z Werb, UCSF) to 
generate F1 transgenic mice heterozygous for Per3 (Neu/Per3+/-). F1 males and females were intercrossed 
to produce the F2 generation consisting of Neu/ Per3+/+, Neu/ Per3+/- and Neu/ Per3-/- animals. 
Identification of animal genotypes is described in the Supplementary Data. 
In the DMBA gavage experiment female mice were examined every three days for sickness or symptoms 
of tumor development for up to 19.7 months. MMTVneu/Per3 transgenic female mice were examined 
weekly for mammary tumor development by palpation for up to 25.8 months. Mice that showed 
significant weight loss, morbidity or excessive tumor burden were sacrificed by cervical dislocation after 
being anesthetized according to the UCSF Animal Care and Use (IACUC) protocol. Tumors and tissues 
were fixed in 4% neutral buffered paraformaldehyde for histological examination. Mice found dead were 
censored from the study. 
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Figure. 1.- Association between Per3 deletion and disease-free survival in breast cancer patients. (a) 
TaqMan copy number analysis of PER3 in 180 lymph node negative breast cancer tumors (top left panel), 
showing decreased survival of patients with PER3 deletions. Patients who received no treatment (36 
patients, (b)) or were treated with anthracycline chemotherapy (85 patients, (c)) showed no effect of 
PER3 deletion. (d) A subset of 59 patients that were ER and/or PGR positive and were treated only with 
tamoxifen showed strong association between survival and low PER3 copy number. 
 
Figure. 2.- Association between PER3 gene expression and survival of breast cancer patients. (a) 
PER3 low expression (red) was found in 122 (30%) patients from both data sets. Kaplan-Meier analysis 
for all patients indicates that those patients with tumors with low expression of PER3 (red) have lower 
disease free survival rates at 10 years than those patients with normal/high expression of PER3 (blue). 
 (b) Comparison of PER3 expression with Estrogen Receptor (ER) status. Low expression of PER3 was 
less common in ER+ tumors, however those patients with ER+ tumors and low PER3 expression show a 
higher risk of recurrence (lower left panel). No effect was seen in patients with ER- tumors. (right panel)  
 
Figure. 3.- Effect of PER3 expression levels on survival according to molecular subtypes. Kaplan–
Meier estimates of Disease-Free Survival among the 413 patients, according to the Per3 expression. 
Patients were stratified using the Sorlie et al.33,36  tumor classification. (a) In the Basal Tumors, the low 
expression of PER3 gene had no effect in patient recurrence however in the Non Basal tumors those 
patients whose tumors had low expression of PER3 showed a significant increase of recurrence. (b) The 
increase in recurrence was observed mainly in the Luminal A and ERBB2+ subgroup of tumors whereas 
no significant difference was observed in the Luminal B subgroup. P values were obtained using  the log-
rank test. 
 
Figure. 4.- Kaplan-Meier Estimates of Overall Survival.  
The different expression levels of Per3 were evaluated in all the patients (a) and the different subgroups 
of patients based on (b) ER positive (c) ER negative, and based on the different molecular subtypes using 
Sorlie et al35,36 classification, (d) Basal, (e) Non Basal, (f) ERBB2+, (g) Luminal A and (h) Luminal B 
tumors. P values were obtained using the log-rank test. 
 
Figure. 5.- Effect of loss of Per3 on tumor susceptibility in two different mouse models. (a) Breast 
cancer incidence in a group of mice treated with 7,12-dimethyl-benz[a]anthracene (DMBA) based in the 
different genotypes (WT +/+, HET +/-, Null -/-) (b) Kaplan-Meier estimates of probability of Tumor Free 
Survival in the group of MMTVneu-PER3 mice.  P values were obtained using the log-rank test. 
  
a Variable   Disease Free Survival  Overall Survival 
    
    Hazard ratio (95% IC) P-value   Hazard ratio (95% IC) P-value 
      
  PER3   2.13 ( 1.40 - 3.24 ) <0.001 2.04 ( 1.34 - 3.10 ) 0.001 
  Tumor Size   1.72 ( 1.13 - 2.63 ) 0.012 2.02 ( 1.31 - 3.12 ) 0.002 
  
Age (< 40 
years)   0.49 ( 0.32 - 0.74 ) 0.001 0.54 ( 0.35 - 0.83 ) 0.005 
  ER   0.75 ( 0.49 - 1.15 ) 0.19 0.53 ( 0.35 - 0.80 ) 0.003 
  Lymph Node    1.36 ( 0.90 - 2.06 ) 0.14 1.85 (1.18 - 2.77 ) 0.007 
  Tumor Grade     
  good   0.93 ( 0.55 - 1.60 ) 0.8 1.05 (0.61 - 1.80 ) 0.87 
  intermediate   1.18 ( 0.74 - 1.89 ) 0.48 1.38 ( 0.87 - 2.20 ) 0.17 
      
                
b Variable Disease Free Survival Overall Survival 
    
    Hazard ratio (95% IC) P-value   Hazard ratio (95% IC) P-value 
      
  PER3   2.92 ( 1.71 – 4.97 )  <0.001 2.63 ( 1.49 – 4.63 )  0.001 
  Tumor Size   1.62 ( 0.96 - 2.63 )  0.072 1.87 ( 1.05 – 3.32 )  0.03 
  
Age (< 40 
years)   0.58 ( 0.33 - 0.99 )  0.047 0.57 ( 0.32 – 1.04 )  0.06 
  ER   All tumors are ER positive  All tumors are ER positive    
  Lymph Node    1.40 ( 0.83 - 2.39 )  0.21 2.07 (1.18 - 2.77 )  0.02 
  Tumor Grade     
  good   1.14 ( 0.59 – 2.23 )  0.69 1.09 (0.54 – 2.24 )  0.8 
  intermediate   1.34 ( 0.73 – 2.46 )  0.34 1.32 ( 0.70 – 2.49 )  0.38 
                
 
Table 1. 
 
a.- Cox proportional hazard ratio multivariate analysis. Risk of distant recurrence or death 
among patients with breast cancer. The analysis included the 413 patients from two different data 
bases 31,32 
b.- Cox proportional hazard ratio multivariate analysis for ER positive samples. Risk of 
distant recurrence or death among patients with breast cancer. The analysis included the 302 
patients with ER positive breast tumors from two different data bases 31,32 
 
 
